Comparison · NCT02564926-27fb02c5
Dapagliflozin vs Glimepiride: HbA1c <7.0% at Week 52
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Dapagliflozin vs Glimepiride: HbA1c <7.0% at Week 52. Trial comparisons, record NCT02564926-27fb02c5. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02564926-27fb02c5
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.482 | 0.357 | 0.61 | wilson | |
| Risk in group 2 | 0.393 | 0.276 | 0.524 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0893 | -0.092 | 0.263 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.23 | 0.803 | 1.88 | log | |
| Odds ratio, group 1 over group 2 | 1.44 | 0.68 | 3.05 | log | |
| Number needed to treat, for one more participant with the outcome on Dapagliflozin than on Glimepiride | 11.2 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Dapagliflozin | Dapagliflozin 10mg + Metformin 1000mg | 27 | 56 | OG000 |
| Group 2 | Glimepiride | Glimepiriide 1-2mg + Metformin 1000mg | 22 | 56 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- HbA1c <7.0% at Week 52
- Description
- HbA1c \<7.0% at Week 52
- Time frame
- 52 weeks
- Population
Source ClinicalTrials.gov
Trial
- Title
- Foxiga Korea Local Phase 4 Study
- NCT number
- NCT02564926
- Phases
- PHASE4
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Dapagliflozin, Glimepiride
- Lead sponsor
- AstraZeneca
- Results first posted
- 2019-08-20
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02564926?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02564926-27fb02c5